Pulmonary Hypertension in Left Heart Disease

RecruitingOBSERVATIONAL
Enrollment

3,000

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

May 31, 2028

Study Completion Date

May 31, 2028

Conditions
Pulmonary HypertensionPulmonary Vascular DiseaseLeft Heart Disease
Interventions
DIAGNOSTIC_TEST

Transthoracic Echocardiography (TTE)

Transthoracic echocardiography using ultrasound waves will be conducted during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization to gather additional measurements of right ventricular function.

DIAGNOSTIC_TEST

Lung ultrasound

A lung ultrasound, which uses sound waves to produce images of the lungs, will be used to assess extravascular lung fluid during the rest and exercise phases of the clinically indicated invasive hemodynamic assessment by right heart catheterization.

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Mayo Clinic

OTHER

NCT05935605 - Pulmonary Hypertension in Left Heart Disease | Biotech Hunter | Biotech Hunter